NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Possible Roche / Novartis merger One month ago ... do with patents on pharmaceutical products as all products on India's essential drug list are not patented." "The fight is going to be closely ...

Financial writer rates Mereo BioPharma stock as Hold despite recent positive data, citing uncertainties around Phase 3 ...

No company wants sub-optimal returns on their product – and pain-management house Medical Developments International (ASX:MVP ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

The report comes as the FDA biosimilar approval list approaches ... the impact these products have had on out-of-pocket costs ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...